Divis Laboratories Limited (NSE: DIVISLAB, BSE: 532488) is a Hyderabad, Telangana-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹2,42,758 Cr, it ranks #35 by market cap among the 6,137 Indian listed companies on FinBizNet, and #1 of 11 in Pharmaceutical CDMO and CRO Services. At ₹8,950.00 (as of 25 Oct 2026), the share price is 8.1% below its 52-week high of ₹9,740.00 and 58.5% above its 52-week low of ₹5,647.50. The share price is up 35.6% over one year and up 23.5% over three months.
| Current Price | ₹8,950.00 |
|---|---|
| Market Cap | ₹2,42,758 Cr |
| NSE Symbol | DIVISLAB |
| BSE Code | 532488 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 93.8 |
| Return on Equity | 16.19% |
| Return on Assets | 10.07% |
| 52-Week Range | ₹5,647.50 – ₹9,740.00 |
| 1-Year Price Change | +35.6% |
| 3-Month Price Change | +23.5% |
| Beta (1Y) | 0.28 |
| Dividend Yield | 0.33% |
| Headquarters | Hyderabad, Telangana |
| Website | www.divislabs.com |
| Revenue | ₹3,080 Cr |
|---|---|
| Net Profit | ₹902 Cr |
| Net Margin | 29.3% |
| EPS (Basic) | ₹33.95 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
1. Segment Adjustment-This segment manufactures and sells active pharmaceutical ingredients and intermediates. 2. Pharmaceuticals-0
1. Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹2,42,758 Cr | 93.8 | 16.19% | ₹3,080 Cr | +35.6% |
| Anthem Biosciences Limited | ₹46,303 Cr | 77.5 | 19.45% | ₹418 Cr | +5.3% |
| Sai Life Sciences Limited | ₹29,513 Cr | 85 | 15.13% | ₹554 Cr | +58.5% |
| Cohance Lifesciences Ltd | ₹17,754 Cr | 97.9 | 5.11% | ₹422 Cr | -49.9% |
| Onesource Specialty Pharma Limited | ₹16,144 Cr | -213 | -1.26% | ₹449 Cr | -27.8% |
| Syngene International Ltd. | ₹15,371 Cr | 50.6 | 6.62% | ₹736 Cr | -42.7% |
| Jubilant Pharmova Ltd | ₹14,958 Cr | 37.3 | 5.96% | ₹2,229 Cr | -12.8% |
| Concord Biotech Ltd | ₹14,008 Cr | 51.7 | 13.54% | ₹257 Cr | -19.5% |
| Blue Jet Healthcare Ltd | ₹9,855 Cr | 35.5 | 19.88% | ₹293 Cr | -29.2% |
Listed by market capitalisation. Ratios are shown for context only.
Divis Laboratories Limited is trading at ₹8,950.00, with a market capitalisation of ₹2,42,758 Cr.
Divis Laboratories Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Divis Laboratories Limited has a P/E of 93.8 and a return on equity of 16.19%.
Divis Laboratories Limited is listed on the NSE under the symbol DIVISLAB and on the BSE under the scrip code 532488.
Divis Laboratories Limited's share price is up 35.6% over one year and up 23.5% over three months. Its 52-week range is ₹5,647.50 to ₹9,740.00.
In Q1 FY27, Divis Laboratories Limited reported revenue of ₹3,080 Cr and net profit of ₹902 Cr, with basic EPS of ₹33.95 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.